ClinicalTrials.gg
CompletedNCT05542979Updated Sep 16, 2022

A Study to Evaluate the Safety, Tolerability of HH-003 Injection in Participants With Chronic Hepatitis B Virus Infection

A Phase 1 interventional study of HH-003 injection and Placebo in Chronic HBV Infection, sponsored by Huahui Health. Completed at 11 sites in China. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2022-09-16.

Sponsored by Huahui Health · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 1 month after the study started (first participant enrolled Aug 2019, registered Sep 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled, multiple-ascending dose phase Ib study of HH-003 injection, which is a monoclonal antibody targeting Hepatitis B virus. This study aims to evaluate the safety, tolerability and pharmacokinetics of HH-003 injection in treatment-naive participants chronically infected with hepatitis B virus.

02

Conditions studied

  • Chronic HBV Infection
03

In context

Lead sponsor

Huahui Health is the lead sponsor of 18 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 45 years old
  • Body weight ≥ 45 kg for men and ≥ 40 kg for women, and 18 kg/m\^2≤≤28 kg/m\^2
  • Positive serum or HBV DNA for at least 6 months,or previous liver results confirm the Hepatitis B
  • HBeAg positive, and 2000 IU/mL\<HBsAg\<100,000 IU/mL
  • Have not received interferon treatment before, and have not received nucleotide/nucleoside analogue treatment within 6 months prior to Screening

Exclusion criteria

Exclusion Criteria:

  • Positive test for antibody (HCV-Ab), treponema pallidum antibody (TP-Ab), or anti- antibody (HIV-Ab)
  • \<100 g/L, \<100,000/mm\^3 (100×10\^9/L), absolute neutrophils count \<1,500/mm\^3 (1.5×10\^9/L)
  • Serum albumin \<35 g/L, (INR)>1.5; serum creatinine >115 μmol/L, (GFR) \<70 mL/min/1.73m\^2(calculated by Modification of Diet in Renal Disease (MDRD) formula); uric acid>540 μmol/L; triglyceride>3.5mmol/L
  • Participants with a history of alcoholic liver disease, moderate or higher nonalcoholic fatty liver disease, liver disease, Gilbert syndrome or other hereditary liver disease, drug-induced liver disease and other chronic liver diseases
  • Participants with a history of progressive liver fibrosis (eg: liver cirrhosis diagnosed by liver histopathological examination, or esophagogastric varices diagnosed by endoscopy)
  • Participants with confirmed or suspected decompensated cirrhosis with complications of ascites, hepatic encephalopathy, gastroesophageal variceal bleeding, and score of B\~C, or with primary liver cancer
  • Alpha Fetoprotein (AFP) >50 ng/ml at screening or the suspected malignant liver mass indicated by imaging
  • Any previous or current malignant neoplasms
  • Breast-feeding or pregnant females
  • Participants who are not suitable to participate in this trial per the Investigator's judgment
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    HH-003 Group

    Drug: HH-003 injection

  • Placebo comparator
    Placebo Group

    Drug: Placebo

Interventions

  • HH-003 injection is administrated via I.V. infusion

  • DrugPlacebo

    Placebo is administrated via I.V. infusion

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Time frame: From the first dose of study drug until Day 57

  2. Peak concentration (Cmax)

    Time frame: From predose to Day 113

  3. Area under the drug-time curve (AUC0-2W)

    Time frame: From predose to Day 113

  4. Area under the drug-time curve (AUClast)

    Time frame: From predose to Day 113

  5. Area under the drug-time curve (AUCinf)

    Time frame: From predose to Day 113

07

Study locations

11 sites
  • Beijing Ditan Hospital,Capital Medical University
    Beijing, Beijing Municipality 100015, China
  • Beijing Friendship Hospital,Capital Medical University
    Beijing, Beijing Municipality 100050, China
  • Beijing Youan Hospital,Capital Medical University
    Beijing, Beijing Municipality 100069, China
  • Mengchao Hepatobiliary Hospital Of Fujian Medical University
    Fuzhou, Fujian 350025, China
  • The First Hospital of Lanzhou University
    Lanzhou, Gansu 730000, China
  • The First Affiliated Hospital Of Zhengzhou University
    Zhengzhou, Henan 450000, China
  • Henan Infectious Disease Hospital(The Sixth Peoples Hospital Of Zhengzhou)
    Zhengzhou, Henan 450006, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Yanbian University Hospital(Yanbian Hospital)
    Yanji, Jilin 133000, China
  • Shandong Public Health Clinical Center
    Jinan, Shandong 250102, China
  • The First Affiliated Hospital,Zhejiang University School Of Medicine
    Hangzhou, Zhejiang 310003, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Mar 2022, 31 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2022
First posted
Sep 16, 2022
StartActual
Aug 5, 2019
Primary completionActual
Mar 15, 2022
CompletionActual
Mar 15, 2022
Last update
Sep 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05542979
Lead sponsor
Huahui Health
Responsible party
Sponsor
First posted
Sep 16, 2022
Start date
Aug 5, 2019
Primary completion
Mar 15, 2022
Completion
Mar 15, 2022
Last update
Sep 16, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Libevitug

Start the discussion